General Hospital Psychiatry
Volume 32, Issue 4 , Pages 401-405 , July 2010

Can antidepressants prevent interferon-alpha-induced depression? A review of the literature

  • Amanda Galvão-de Almeida, M.D.

      Affiliations

    • Universidade Federal da Bahia, Teaching Hospital-Psychiatry Service, 40110-909 Bahia, Brazil
    • Universidade Federal de São Paulo, Department of Psychiatry and Laboratório Interdisciplinar de Neurociências Clínicas (LiNC), 04026-001 São Paulo, Brazil
    • Corresponding Author InformationCorresponding author. Hospital Universitário Professor Edgard Santos, Serviço de Psiquiatria, 3°. Andar/40110-909. Salvador, BA, Brazil. Tel.: +55 71 3351 4111; fax: +55 11 3351 4111.
    • ,
  • Camila Guindalini, Ph.D.

      Affiliations

    • Universidade Federal de São Paulo, Department of Psychiatry and Laboratório Interdisciplinar de Neurociências Clínicas (LiNC), 04026-001 São Paulo, Brazil
    • Universidade Federal de São Paulo, Department of Psychobiology, 04023-062 São Paulo, Brazil
    • ,
  • Susana Batista-Neves, M.D., M.Sc.

      Affiliations

    • Universidade Federal da Bahia, Teaching Hospital-Psychiatry Service, 40110-909 Bahia, Brazil
    • ,
  • Irismar R. de Oliveira, M.D., Ph.D.

      Affiliations

    • Universidade Federal da Bahia, Teaching Hospital-Psychiatry Service, 40110-909 Bahia, Brazil
    • ,
  • Ângela Miranda-Scippa, M.D., Ph.D.

      Affiliations

    • Universidade Federal da Bahia, Teaching Hospital-Psychiatry Service, 40110-909 Bahia, Brazil
    • ,
  • Lucas C. Quarantini, M.D., Ph.D.

      Affiliations

    • Universidade Federal da Bahia, Teaching Hospital-Psychiatry Service, 40110-909 Bahia, Brazil

Received 20 October 2009 ,Accepted 2 March 2010.

References 

  1. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26(5):643–652
  2. Asnis GM, De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol. 2006;40(4):322–335
  3. Asnis GM, De la Garza R, Kohn SR, et al. IFN-induced depression: a role for NSAIDs. Psychopharmacol Bull. 2003;37(3):29–50
  4. Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics. 2000;41(5):439–441
  5. Keefe B. Interferon-induced depression in hepatitis C: an update. Curr Psychiatry Rep. 2007;9(3):255–261
  6. Arora A, Attwood J. Common skin cancers and their precursors. Surg Clin North Am. 2009;89(3):703–712
  7. Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103(1-3):83–90
  8. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004;56(11):819–824
  9. Quarantini LC, Bressan RA, Galvao A, et al. Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients. Liver Int. 2007;27(8):1098–1102
  10. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1163–1174
  11. Hunt CM, Dominitz JA, Bute BP, et al. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci. 1997;42(12):2482–2486
  12. Forton DM, Taylor-Robinson SD, Thomas HC. Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2006;18(4):333–338
  13. Quarantini LC, Miranda-Scippa A, Batista-Neves S, et al. A neuropsychological study comparing patients infected with HCV and HBV without psychiatric comorbidities. J Med Virol. 2009;81(7):1184–1188
  14. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340(16):1228–1233
  15. Quarantini LC, Miranda-Scippa A, Batista-Neves S, et al. The effect of early virological response in health-related quality of life in HCV-infected patients. J Med Virol. 2008;80(3):419–423
  16. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942–947
  17. Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008;57(4):531–536
  18. Gleason OC, Fucci JC, Yates WR, Philipsen MA. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C — A pilot study. Dig Dis Sci. 2007;52(10):2557–2563
  19. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–966
  20. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42(6):793–798
  21. Kraus MR, Schäfer A, Al-Taie O, et al. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat. 2005;12(1):96–100
  22. Robaeys G, Wichers MC, De Bie J, et al. Does antidepressant medication in patients with hepatitis C undergoing interferon alpha treatment reduce therapeutic efficacy?. Gut. 2009;58(1):145
  23. Kraus MR, Schäfer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med. 2001;345(5):375–376
  24. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602
  25. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627
  26. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163(1):59–64
  27. Quarantini LC, Miranda-Scippa A, Schinoni MI, et al. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol. 2006;29(3):138–143
  28. Cuijpers P, van Straten A, Smit F, et al. Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. Am J Psychiatry. 2008;165(10):1272–1280
  29. Dbouk N, Arguedas MR, Sheikh A. Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C. Dig Dis Sci. 2008;53(4):1100–1106
  30. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66(1):41–48
  31. Ozkan M, Corapcioglu A, Balcioglu I, et al. Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatry Med. 2006;36(3):283–297
  32. Batista-Neves SC, Quarantini LC, de Almeida AG, et al. High frequency of unrecognized mental disorders in HCV-infected patients. Gen Hosp Psychiatry. 2008;30(1):80–82
  33. Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry. 2008;
  34. Kraus MR, Al-Taie O, Schafer A, et al. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology. 2007;132(4):1279–1286
  35. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry. 2009;65(4):344–348

PII: S0163-8343(10)00051-4

doi: 10.1016/j.genhosppsych.2010.03.001

General Hospital Psychiatry
Volume 32, Issue 4 , Pages 401-405 , July 2010

Article Tools